Literature DB >> 8750357

Screening for CGG trinucleotide repeat expansion in the fragile X mental retardation 1 gene in schizophrenic patients.

E Jönsson1, E Björck, J Wahlström, P Gustavsson, G Sedvall.   

Abstract

Patients diagnosed using DSM-III-R criteria as having schizophrenia and other related disorders (n = 128) were assessed for CGG trinucleotide repeat expansion in the fragile X mental retardation 1 (FMR-1) gene. One subject, a woman with schizophreniform disorder, was found to have a premutation of the gene. Her case report is given. The present investigation supports the view that mutation or premutation of the FMR-1 gene is not of importance for the aetiology of the vast majority of schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8750357     DOI: 10.1097/00041444-199524000-00002

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  5 in total

1.  Fragile X mental retardation protein levels are decreased in major psychiatric disorders.

Authors:  S Hossein Fatemi; Rachel E Kneeland; Stephanie B Liesch; Timothy D Folsom
Journal:  Schizophr Res       Date:  2010-08-19       Impact factor: 4.939

Review 2.  The role of fragile X mental retardation protein in major mental disorders.

Authors:  S Hossein Fatemi; Timothy D Folsom
Journal:  Neuropharmacology       Date:  2010-11-22       Impact factor: 5.250

Review 3.  FMRP and CYFIP1 at the Synapse and Their Role in Psychiatric Vulnerability.

Authors:  Nicholas E Clifton; Kerrie L Thomas; Lawrence S Wilkinson; Jeremy Hall; Simon Trent
Journal:  Complex Psychiatry       Date:  2020-03-03

4.  mRNA and protein expression for novel GABAA receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway.

Authors:  S H Fatemi; T D Folsom; R J Rooney; P D Thuras
Journal:  Transl Psychiatry       Date:  2013-06-18       Impact factor: 6.222

Review 5.  The FMRP regulon: from targets to disease convergence.

Authors:  Esperanza Fernández; Nicholas Rajan; Claudia Bagni
Journal:  Front Neurosci       Date:  2013-10-24       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.